Do MEFV mutations influence arterial stiffness in FMF patients?

Memnune Sena Ulu, Akif Acay, Ahmet Ahsen, Şeref Yuksel, Gürsel Acartürk, Mustafa Solak


Background: Pulse wave velocity (PWV) is the most used technique to evaluate the arterial elasticity, which is an early indicator of atherosclerosis. We aimed to evaluate if MEFV Mutations influence arterial stiffness in patients with Familial Mediterranean fever (FMF)

Methods: 70 patients diagnosed with FMF and 50 age-and sex-matched controls were included in the study. Genetic analysis of the patients was performed. After the measurement of PWV; the presence of AS was determined.

Results: Mean PWV value and arterial stiffness frequency of FMF patients were significantly higher than the control group (p <0.001, p <0.001) respectively. In addition, FMF patients with M694Vmutations had higher PWV values and arterial stiffness frequency than those with other mutations. (p=0.045), (p=0.001). There were no differences within all genetic mutation types in terms of arterial stiffness frequency.

Conclusions: As a result, due to subclinical inflammation in FMF patients, they have risk for cardiovascular complications. These patients especially those with M694Vmutations have to be followed more closely because of increased cardiovascular risk and PWV measurements may be a good tool to detect early development of atherosclerosis.



Chronic inflammatory disease, Familial mediterranean fever, MEFV mutations, Pulse wave velocity, Arterial stiffness

Full Text:



Sohar E, Gafni J, Pras M, Heller H. Familial Mediterranean fever. A survey of 470 cases and review of the literature. Am J Med 1967;43(2):227-53.

Berkun Y, Eisenstein E, Ben-Chetrit E. FMF - clinical features, new treatments and the role of genetic modifiers: a critical digest of the 2010-2012 literature. Clin Exp Rheumatol 2012;30(3 Suppl 72):90-5.

Ben-Chetrit E, Touitou I. The impact of MEFV gene identification on FMF: an appraisal after 15 years. Clin Exp Rheumatol 2012;30(3 Suppl 72):S3-6.

Unverdi S, Inal S, Ceri M, Unverdi H, Batgi H, Tuna R, Ozturk MA, Guz G, Duranay M. Is colchicine therapy effective in all patients with secondary amyloidosis? Ren Fail 2013;35(8):1071-4.

Colak B, Gurlek B, Yegin ZA, Deger SM, Elbek S, Pasaoglu H, Dogan I, Ozturk MA, Unal S, Guz G. The relationship between the MEFV genotype, clinical features, and cytokine-inflammatory activities in patients with familial mediterranean fever. Ren Fail. 2008;30(2):187-91.

Onat A, Direskeneli H. Excess cardiovascular risk in inflammatory rheumatic diseases: pathophysiology and targeted therapy. Curr Pharm Des 2012;18(11):1465-77.

Park S, Lakatta EG. Role of inflammation in the pathogenesis of arterial stiffness. Yonsei Med J 2012;53(2):258-61.

Deloach SS, Townsend RR. ‘Vascular stiffness: Its Measurement and Significance for Epidemiologic and Outcome Studies.’ Clinical Journal of American Society of Nephrology 2008;3:184-92.

Yildiz M, Soy M, Kurum T, Ozbay G. Increased pulse wave velocity and shortened pulse wave propagation time in young patients with rheumatoid arthritis. Can J Cardiol 2004;20(11):1097-100.

Zeng Y, Li M, Xu D, Hou Y, Wang Q, Fang Q, Sun Q, Zhang S, Zeng X. Macrovascular involvement in systemic sclerosis: evidence of correlation with disease activity. Clin Exp Rheumatol 2012;30(2 Suppl 71):S76-80.

Livneh A, Langevitz P, Zemer D et al. Criteria for the diagnosis of Familial Mediterranean Fever. Arthritis Rheum 1997:40.1879-85.

Reference Values for Arterial Stiffness' Collaboration. Determinants of pulse wave velocity in healthy people and in the presence of cardiovascular risk factors: 'establishing normal and reference values'. Eur Heart J 2010;31(19):2338-50.

Yildiz M, Masatlioglu S, Seymen P, Aytac E, Sahin B, Seymen HO. The carotid-femoral (aortic) pulse wave velocity as a marker of arterial stiffness in familial Mediterranean fever. Can J Cardiol 2006;22(13):1127-31.

Sari I, Karaoglu O, Can G, Akar S, Gulcu A, Birlik M, Akkoc N, Tunca M, Goktay Y, Onen F. Early ultrasonographic markers of atherosclerosis in patients with familial Mediterranean fever. Clin Rheumatol 2007;26(9):1467-73.

Touitou I. The spectrum of familial Mediterranean fever (FMF) mutations. Eur J Hum Genet 2001;9:473-83.

Akdogan A, Calguneri M, Yavuz B, Arslan EB, Kalyoncu U, Sahiner L, et al. Are familial Mediterranean fever (FMF) patients at increased risk for atherosclerosis? Impaired endothelial function and increased intima media thickness are found in FMF. J Am Coll Cardiol 2006;48(11):2351-3.